Looking at PE 22-28 as a fast‑acting antidepressant – thoughts?

Posted by tiredmira in Research & News - 2 points, 0 comments.

I was reading the PE 22-28 entry on the site and it stuck with me because it’s described as a spadin‑derived peptide that blocks the TREK‑1 potassium channel, which in animal models leads to rapid antidepressant‑like effects and increased neurogenesis. The page says the mechanism is selective TREK‑1 blockade, boosting serotonergic signaling and synaptogenesis faster than typical SSRIs in preclinical tests. I’ve been tracking my mood with HRV and daily logs for a while, and I’m always curious about compounds that might shift the needle quickly without the weeks‑long wait of standard meds.

Of course the safety and human efficacy data are still unknown, which makes me cautious. Has anyone here come across any recent human trials or even solid anecdotal reports on PE 22-28? I’d love to hear if the preclinical promise is translating anywhere yet or if it’s still strictly a research‑only molecule.

Community discussion - research and educational context only. Not medical advice.